Back
Axsome Therapeutics, Inc. (AXSM)
PharmaceuticalsAXSM · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$248.78
+1.33%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$-3.68
ROE
-349.4%
Gross margin
92.6%
Debt/Equity
4.03x
Revenue growth
57.4%
Axsome Therapeutics, Inc. — company intelligence
Earnings surprises
Q1 2026$-1.26 vs $-0.91 est-37.9%
Q4 2025$-0.56 vs $-0.68 est+18.0%
Q3 2025$-0.94 vs $-0.88 est-6.5%
Q2 2025$-0.97 vs $-1.12 est+13.3%
Insider activity · 90 days
9 buys8 sellsnet +42,918 shares
TABUTEAU HERRIOTother 49,666 · Jul 1, 2026
JEFFS ROGERSell 286 · Jun 11, 2026
JEFFS ROGERSell 286 · Jun 10, 2026
Recent SEC filings
4 — Insider transaction reportJul 1, 2026
4 — Insider transaction reportJun 11, 2026
4 — Insider transaction reportJun 10, 2026
Latest news
Axsome Therapeutics Doses First Patient In FOCUS-2 Phase 3 Trial Of Solriamfetol For Children With Attention Deficit Hyperactivity Disorder — Benzinga · 4d ago
Axsome Therapeutics Announces First Patient Dosed In FOCUS-3 Phase 3 Trial Evaluating Solriamfetol As Treatment For Adolescents With Attention Deficit Hyperactivity Disorder — Benzinga · 2w ago
TD Cowen Maintains Buy on Axsome Therapeutics, Raises Price Target to $300 — Benzinga · 3w ago
Axsome to Present New Sleep Disorder Data at SLEEP 2026, To Highlight AXS-12 and Solriamfetol Data for Narcolepsy and OSA — Benzinga · 3w ago
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says — Yahoo · 4w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Axsome Therapeutics, Inc.
Weekly undervalued picks (like AXSM)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.